DelMar Pharmaceuticals receives approval to initiate phase 2 clinical trial in China
DelMar Pharmaceuticals announced that the Human Genetic Resources Administration of China, has approved the Company's application to initiate a Phase 2 safety and efficacy study of its lead product candidate VAL-083 in newly diagnosed MGMT-unmethylated glioblastoma multiforme. July 24, 2017